Dengue Fever Vaccine Study
An exciting research study, the Dengue Fever Vaccine Study aims to test the effectiveness and safety of an experimental vaccine for the prevention of dengue fever. This vaccine, but a different lot, has already been tested in another trial and was generally well-tolerated. This current research trial will evaluate a new lot of this vaccine, and the results will be compared with those of the previous trial.
The study has been designed for maximum volunteer safety and has been approved by the U.S. Food and Drug Administration (FDA), the UVM Institutional Review Board (IRB) and the UVM Biosafety Committee (IBC).
Volunteers' responsibilities will be fully explained during the first visit. These include one screening visit, two dosing visits and 22 additional follow up visits. Volunteers will receive either the research vaccine or a placebo, and will be asked to keep a daily record of their temperatures over the first 16 days of the study.
Dengue fever is rare in this country but common in most tropical and subtropical regions of the world, where about 50-100 million cases have been reported per year. We hope that this research study will lead to a vaccine that will protect human populations against this viral infection. Dengue virus is an RNA virus, transmitted by the Aedes egypti mosquito, which can cause a significant febrile illness (Dengue fever). Most individuals spontaneously recover from primary infection; however secondary, infections are more frequently associated severe complications, including shock and bleeding disorders. Dengue viruses cause 50-100 million infections each year, with 500,000 hospitalizations. Although most infections occur in tropical and subtropical areas, global warming has increased the risk of Dengue becoming a significant risk in areas where the disease was previously eradicated, including the United States. The development of Dengue vaccines is a priority of the National Institutes of Health. Work on dengue vaccines is a new direction for the laboratory and Vaccine Testing Center. Over the last three years, the lab has been working with collaborators to better define cellular immune responses to live, attenuated dengue vaccines. This work will continue for the next couple of years here at the Vaccine Testing Center.
Last modified July 22 2013 01:09 PM